Literature DB >> 9716026

Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma.

T Fukuura1, C Miki, T Inoue, K Matsumoto, H Suzuki.   

Abstract

To evaluate the clinical significance of serum levels of hepatocyte growth factor (HGF) in colorectal cancer patients, we measured the venous and portal concentrations of HGF in 60 patients. The tissue concentrations in the tumour and adjacent normal mucosa were also determined. The serum HGF concentration for the peripheral venous blood of the patients was significantly higher than that in normal controls. The content of HGF in cancer tissue was also significantly higher than that in normal mucosa, and it was correlated with the serum HGF concentration for the peripheral venous blood. The serum concentration of HGF reflected pathological features, including tumour size and lymph node or liver metastasis, and it showed an association with various preoperative nutritional parameters and the preoperative haemoglobin level. The serum HGF concentration was also correlated with the serum concentrations of immunosuppressive acidic protein and interleukin-6, indices of the host's immunological condition. Serum HGF seems to be a useful index of the disease status of patients with colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716026      PMCID: PMC2063100          DOI: 10.1038/bjc.1998.514

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  64 in total

Review 1.  Tumor interactions with the vasculature: angiogenesis and tumor metastasis.

Authors:  C H Blood; B R Zetter
Journal:  Biochim Biophys Acta       Date:  1990-06-01

2.  Scatter factor induces blood vessel formation in vivo.

Authors:  D S Grant; H K Kleinman; I D Goldberg; M M Bhargava; B J Nickoloff; J L Kinsella; P Polverini; E M Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

3.  Identification and characterization of "injurin," an inducer of expression of the gene for hepatocyte growth factor.

Authors:  K Matsumoto; H Tajima; M Hamanoue; S Kohno; T Kinoshita; T Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

4.  E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration.

Authors:  B Mayer; J P Johnson; F Leitl; K W Jauch; M M Heiss; F W Schildberg; W Birchmeier; I Funke
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

5.  Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species.

Authors:  H Tajima; K Matsumoto; T Nakamura
Journal:  Exp Cell Res       Date:  1992-10       Impact factor: 3.905

6.  Changes in serum human hepatocyte growth factor levels after transcatheter arterial embolization and partial hepatectomy.

Authors:  A Kaneko; N Hayashi; Y Tanaka; T Ito; A Kasahara; M Kubo; T Mukuda; H Fusamoto; T Kamada
Journal:  Am J Gastroenterol       Date:  1992-08       Impact factor: 10.864

7.  Production of scatter factor-like activity by a nitrosamine-induced pancreatic cancer cell line.

Authors:  M Hirota; H Egami; S Corra; H Fujii; W G Chaney; A Rizzino; P M Pour
Journal:  Carcinogenesis       Date:  1993-02       Impact factor: 4.944

8.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.

Authors:  F Bussolino; M F Di Renzo; M Ziche; E Bocchietto; M Olivero; L Naldini; G Gaudino; L Tamagnone; A Coffer; P M Comoglio
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

9.  Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts.

Authors:  K Rygaard; T Nakamura; M Spang-Thomsen
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

10.  Human lung cancer cell line producing hepatocyte growth factor/scatter factor.

Authors:  Y Yoshinaga; S Fujita; M Gotoh; T Nakamura; M Kikuchi; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  14 in total

1.  Screening of hub genes and pathways in colorectal cancer with microarray technology.

Authors:  Yonggang Wang; Tianying Zheng
Journal:  Pathol Oncol Res       Date:  2014-02-07       Impact factor: 3.201

2.  Serum hepatocyte growth factor as an index of extensive catabolism of patients awaiting liver transplantation.

Authors:  C Miki; A D Mayer; J A Buckels; K Iriyama; H Suzuki; P McMaster
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

3.  The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon.

Authors:  X T Wang; Y Nagaba; H S Cross; F Wrba; L Zhang; S E Guggino
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

4.  Administration of anti-vascular endothelial growth factor antibody following hepatectomy does not inhibit remnant liver regeneration or growth of remnant metastases.

Authors:  Kazuhiko Kasuya; Minako Suzuki; Yuichi Nagakawa; Yoshiaki Suzuki; Satoru Kikuchi; Bunso Kyo; Takaaki Matsudo; Takao Itoi; Akihiko Tsuchida; Tatsuya Aoki
Journal:  Exp Ther Med       Date:  2011-12-06       Impact factor: 2.447

Review 5.  Role of cMET in the development and progression of colorectal cancer.

Authors:  Juan Carlos Samamé Pérez-Vargas; Pamela Biondani; Claudia Maggi; Manuela Gariboldi; Annunziata Gloghini; Alessandro Inno; Chiara Costanza Volpi; Ambra Vittoria Gualeni; Maria di Bartolomeo; Filippo de Braud; Alessandra Castano; Ilaria Bossi; Filippo Pietrantonio
Journal:  Int J Mol Sci       Date:  2013-09-03       Impact factor: 5.923

6.  c-Met targeting enhances the effect of irradiation and chemical agents against malignant colon cells harboring a KRAS mutation.

Authors:  Yingbo Li; Jinxi Wang; Xing Gao; Weihua Han; Yongxiang Zheng; Huan Xu; Chuanling Zhang; Qiuchen He; Lihe Zhang; Zhongxin Li; Demin Zhou
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

Review 7.  Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment.

Authors:  Benjamin Yaw Owusu; Robert Galemmo; James Janetka; Lidija Klampfer
Journal:  Cancers (Basel)       Date:  2017-04-17       Impact factor: 6.639

8.  Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

Authors:  F Cappuzzo; M Varella-Garcia; G Finocchiaro; M Skokan; S Gajapathy; C Carnaghi; L Rimassa; E Rossi; C Ligorio; L Di Tommaso; A J Holmes; L Toschi; G Tallini; A Destro; M Roncalli; A Santoro; P A Jänne
Journal:  Br J Cancer       Date:  2008-06-24       Impact factor: 7.640

9.  Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.

Authors:  Benjamin Y Owusu; Namita Bansal; Phanindra K M Venukadasula; Larry J Ross; Troy E Messick; Sanjay Goel; Robert A Galemmo; Lidija Klampfer
Journal:  Oncotarget       Date:  2016-05-17

Review 10.  Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression.

Authors:  Heydi Noriega-Guerra; Vanessa Morais Freitas
Journal:  Int J Mol Sci       Date:  2018-10-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.